This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.
An analysis of the CANTOS trial showed that IL-1β inhibition with canakinumab reduced total number of serious CV events compared to placebo in patients with prior MI and subclinical inflammation.
Investigators of the LoDoCo2 trial present the design and the major findings of this trial which evaluated colchicine in patients with chronic coronary disease.
Elevated Lp(a) levels were associated with greater risk of MACE in optimally treated patients with high-risk vascular disease when hsCRP levels ≥2 mg/L, but not in those with hsCRP levels <2 mg/L.
Elevated Lp(a) contributes to pro-inflammatory gene expression of monocytes in both healthy subjects and CVD patients. Potent Lp(a)-lowering reduced the pro-inflammatory state of circulating monocytes.
Relationships between inflammation, LDL-c and CV risk have not much changed compared to findings from two decades ago. Those with highest levels of IL-6 or hsCRP and highest levels of LDL-c have highest risk of MACE.
Inclisiran, an siRNA against PCSK9, did not result in adverse effects on measures of inflammation, immune activation and platelets. No clinical immunogenicity AEs were observed.
In an analysis of two large U.S. cohorts, higher olive oil intake was associated with lower risk of major CVD and CHD risk compared to those consuming olive oil <1 per month.
This viewpoint article draws attention towards acute and possible long-term implications of coronavirus infections, such as COVID-19, on the cardiovascular system.
Lp(a) meeting Jeffrey Kroon presents his study on inflammatory mechanisms driving CV risk in patients with high Lp(a) levels and a potential new strategy to reduce atherogenesis in these patients.
Several studies suggest that a healthy Nordic diet, which differs from the Mediterranean diet in that it contains berries and uses canola instead of olive oil, has beneficial effects, but the evidence is limited.
Patients with ACS who received prasugrel before PCI, showed less endothelial dysfunction and platelet aggregation, while those on clopidogrel and ticagrelor did not, nor did treatment after PCI.